Samsung Biologics proposed acquisition marks a decisive move to consolidate its position as a global contract development and manufacturing organization
Journals
Editor's Guest
Ensuring Excellent Mobile Connectivity for...
Technology in Cancer Care: A story of evolving...
Bringing Shop Floor to Manufacturer's palm:...
Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide
Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker
Samsung Biologics expands into peptides with $1.8b PolyPeptide deal
Samsung Biologics to acquire PolyPeptide for $1.8 bil. - The Korea Times
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal
Korean firm bids CHF1.5bn for Swiss pharma supplier Polypeptide
Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
SAN DIEGO — Samsung Biologics is accelerating research and development efforts to strengthen its position in the contract…
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with…
Samsung Biologics offers $1.8B for Swiss CDMO PolyPeptide, expanding beyond biologics into peptide APIs and the booming GLP-1…
Samsung Epis Holdings has opened its first biopharmaceutical research and development center in China focused on antibody-drug…
On a quest to bolster its life-sci contracting bona fides, self-described “multifaceted manufacturer” Kimball Electronics is…
Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the…
